months. The initial response to treatment was dramatic in 3/6 cases (with improvement of at least two grades on the MRC scale in the five more severely affected muscles). The final evaluation showed a good result in 416 cases, but the conduction blocks were not significantly reduced. In 13 other cases with polyneuropathy associated with IgM monoclonal gammopathy of unknown significance, IVIg was of benefit, with improvement of at least one grade on the Prineas score, in 4/7 cases previously treated with immunosuppression and 2/3 cases not treated before IVIg. In the last group of four patients with polyneuropathy and IgG monoclonal gammopathy, IVIg was followed by clinical improvement in the two cases with a chronic demyelinating polyneuropathy.
Intravenous human immune globulin (IVIg) has been proposed for the treatment Antibodies directed to GM1 ganglioside in We treated (preliminary reports in three cases'9) six patients with multifocal motor neuropathy and conduction blocks. Clinical and electrophysiological data are summarised in table 1. There were six men aged 34 to 50. The course of the peripheral neuropathy ranged from three to 22 years, but the diagnosis was established on electrophysiological criteria during the last four years. Except for case 6, who had a focal motor involvement of the right radial nerve, all patients had a motor multifocal neuropathy with at least two partial conduction blocks defined with the following criteria: > 50% reduction in both the compound muscle action potentials (CMAP) amplitude and the negative peak area on proximal stimulation compared with the distally stimulated response, with a < 15% change in the negative peak duration. Anti-GM1 ganglioside antibody titres were measured by enzyme-linked immunosorbent assay (ELISA) and immunodetection on thin-layer chromatography (TLC) according to methods previously reported20: 4/6 patients (cases 2, 4, 5 and 6) had significantly high titres. All patients received IVIg (Bio-Transfusion) at doses varying from 1-6 to 2A4 mg/kg over a period of two to five days, every month during three to 13 months. For the follow up, the same examiner measured the strength of each patient at baseline and before/after each series of infusions, using both the MRC scale and a functional evaluation (adapted from the Rankin score used for CIDP).
The results are summarised in 
